Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
Authors
Keywords
-
Journal
CNS DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-19
DOI
10.1007/s40263-018-0539-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor
- (2018) Annalaura Sabatucci et al. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
- Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans
- (2018) Patrick D. Skosnik et al. NEUROPHARMACOLOGY
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- (2018) Douglas L. Boggs et al. PSYCHOPHARMACOLOGY
- Familial abnormalities of endocannabinoid signaling in schizophrenia
- (2018) Dagmar Koethe et al. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
- Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial
- (2017) Ladan Kashani et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice
- (2017) A Busquets-Garcia et al. MOLECULAR PSYCHIATRY
- “Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York
- (2017) Axel J. Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pregnenolone does not interfere with the effects of cannabinoids on synaptic transmission in the cerebellum and the nucleus accumbens
- (2017) Anna Krohmer et al. PHARMACOLOGICAL RESEARCH
- Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice
- (2016) Andreza B. Sonego et al. BEHAVIOURAL BRAIN RESEARCH
- Reduced Brain Cannabinoid Receptor Availability in Schizophrenia
- (2016) Mohini Ranganathan et al. BIOLOGICAL PSYCHIATRY
- Therapeutic Potential of Cannabinoids in Psychosis
- (2016) F. Markus Leweke et al. BIOLOGICAL PSYCHIATRY
- Association Between Cannabis and Psychosis: Epidemiologic Evidence
- (2016) Suzanne H. Gage et al. BIOLOGICAL PSYCHIATRY
- An Introduction to the Endogenous Cannabinoid System
- (2016) Hui-Chen Lu et al. BIOLOGICAL PSYCHIATRY
- Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis
- (2016) Anahita Bassir Nia et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
- (2016) P Seeman Translational Psychiatry
- Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
- (2015) John M McPartland et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
- (2015) R B Laprairie et al. BRITISH JOURNAL OF PHARMACOLOGY
- Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- (2015) Matthew W. Elmes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia
- (2015) David D Aguilar et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Inflammation in schizophrenia: A question of balance
- (2015) Juan C. Leza et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Molecular Targets of Cannabidiol in Neurological Disorders
- (2015) Clementino Ibeas Bih et al. Neurotherapeutics
- Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
- (2014) Fabio Arturo Iannotti et al. ACS Chemical Neuroscience
- The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
- (2014) Thomas R. Insel AMERICAN JOURNAL OF PSYCHIATRY
- Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
- (2014) Marisol S. Castaneto et al. DRUG AND ALCOHOL DEPENDENCE
- Cannabinoid 1 and Transient Receptor Potential Vanilloid 1 Receptors Discretely Modulate Evoked Glutamate Separately from Spontaneous Glutamate Transmission
- (2014) J. A. Fawley et al. JOURNAL OF NEUROSCIENCE
- Early phytocannabinoid chemistry to endocannabinoids and beyond
- (2014) Raphael Mechoulam et al. NATURE REVIEWS NEUROSCIENCE
- Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: An 8-week, double-blind, randomized add-on two-center trial
- (2014) Michael S. Ritsner et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Cannabis use, gender and age of onset of schizophrenia: Data from the ÆSOP study
- (2014) Kim Donoghue et al. PSYCHIATRY RESEARCH
- Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia
- (2014) Christine E. Marx et al. PSYCHOPHARMACOLOGY
- Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia
- (2014) David W. Volk et al. SCHIZOPHRENIA RESEARCH
- Pregnenolone Can Protect the Brain from Cannabis Intoxication
- (2014) Monique Vallée et al. SCIENCE
- Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms
- (2013) Celia J. A. Morgan et al. BRITISH JOURNAL OF PSYCHIATRY
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
- (2013) Jenny Ceccarini et al. NEUROIMAGE
- Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice
- (2013) Felipe V. Gomes et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users
- (2013) M. Di Forti et al. SCHIZOPHRENIA BULLETIN
- Multiple Functions of Endocannabinoid Signaling in the Brain
- (2012) István Katona et al. Annual Review of Neuroscience
- Anandamide Dysfunction in Prodromal and Established Psychosis
- (2012) F. Markus Leweke CURRENT PHARMACEUTICAL DESIGN
- A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
- (2012) Aitor G. Granja et al. Journal of Neuroimmune Pharmacology
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
- (2012) Amir Englund et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia
- (2012) Kimberly J. Jenko et al. SCHIZOPHRENIA RESEARCH
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Cannabis Use and Earlier Onset of Psychosis
- (2011) Matthew Large et al. ARCHIVES OF GENERAL PSYCHIATRY
- Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
- (2011) EM Rock et al. BRITISH JOURNAL OF PHARMACOLOGY
- Fatty Acid-binding Proteins TransportN-Acylethanolamines to Nuclear Receptors and Are Targets of Endocannabinoid Transport Inhibitors
- (2011) Martin Kaczocha et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Grand challenges in global mental health
- (2011) Pamela Y. Collins et al. NATURE
- Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex
- (2011) Victoria S Dalton et al. NEUROPSYCHOPHARMACOLOGY
- Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial
- (2011) Douglas L. Boggs et al. SCHIZOPHRENIA RESEARCH
- Effects of cannabinoids and cannabinoid-enrichedCannabisextracts on TRP channels and endocannabinoid metabolic enzymes
- (2010) Luciano De Petrocellis et al. BRITISH JOURNAL OF PHARMACOLOGY
- Psychosis reactivity to cannabis use in daily life: an experience sampling study
- (2010) Cécile Henquet et al. BRITISH JOURNAL OF PSYCHIATRY
- Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder
- (2010) Michael S. Ritsner et al. JOURNAL OF CLINICAL PSYCHIATRY
- Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia
- (2010) Deanna L. Kelly et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR
- (2010) Dean F. Wong et al. NEUROIMAGE
- Disruption of Frontal Theta Coherence by Δ9-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms
- (2010) Paul D Morrison et al. NEUROPSYCHOPHARMACOLOGY
- Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder
- (2010) Stephen M Eggan et al. NEUROPSYCHOPHARMACOLOGY
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
- (2010) Jaime E. C. Hallak et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing
- (2009) Paolo Fusar-Poli et al. ARCHIVES OF GENERAL PSYCHIATRY
- Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis
- (2009) Dagmar Koethe et al. BRITISH JOURNAL OF PSYCHIATRY
- High-potency cannabis and the risk of psychosis
- (2009) Marta Di Forti et al. BRITISH JOURNAL OF PSYCHIATRY
- Time-dependent vascular actions of cannabidiol in the rat aorta
- (2009) Saoirse E. O'Sullivan et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Synthetic Δ-9-Tetrahydrocannabinol (Dronabinol) Can Improve the Symptoms of Schizophrenia
- (2009) Glenn Schwarcz et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?
- (2009) Volker Auwärter et al. JOURNAL OF MASS SPECTROMETRY
- Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
- (2009) N. A. Jones et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
- (2009) Christine E Marx et al. NEUROPSYCHOPHARMACOLOGY
- Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo
- (2009) J. Z. Long et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of intracellular carriers for the endocannabinoid anandamide
- (2009) M. Kaczocha et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning
- (2009) P. D. Morrison et al. PSYCHOLOGICAL MEDICINE
- Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment
- (2009) Leyre Urigüen et al. PSYCHOPHARMACOLOGY
- Weight effects associated with antipsychotics: A comprehensive database analysis
- (2009) Bruce Parsons et al. SCHIZOPHRENIA RESEARCH
- Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia
- (2008) Stephen M. Eggan et al. ARCHIVES OF GENERAL PSYCHIATRY
- Cannabinoid Receptors: Where They are and What They do
- (2008) K. Mackie JOURNAL OF NEUROENDOCRINOLOGY
- Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy
- (2008) Stéphane Potvin et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
- (2008) Jonathan Z Long et al. Nature Chemical Biology
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
- (2007) A Thomas et al. BRITISH JOURNAL OF PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started